Table 2 Outcomes between study groups
Outcomes | Study group (n = 69) | Comparison group (n = 57) | Risk Ratio (95%CI) | p-value |
|---|---|---|---|---|
Improved seizures (≥ 50% SFR) | 23 (33.3%) | 7 (12.3%) | 2.7 (1.3–5.9) | 0.006 |
Status epilepticus | 2 (2.9%) | 8 (14.0%) | 0.21 (0.05–0.93) | 0.042 |
Escalation of ASMs | 3 (4.4%) | 11 (19.3%) | 0.23 (0.07–0.77) | 0.010 |
Nausea | 11 (15.9%) | 6 (10.5%) | 1.5 (0.60–3.8) | 0.376 |
Vomiting | 6 (8.7%) | 2 (3.5%) | 2.5 (0.52–11.8) | 0.292 |
Diarrhea | 8 (11.6%) | 3 (5.3%) | 2.2 (0.61–7.9) | 0.342 |
Skin rash | 3 (4.4%) | 1 (1.8%) | 2.5 (0.27–23.2) | 0.626 |